CA2239624A1 - Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists - Google Patents

Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists

Info

Publication number
CA2239624A1
CA2239624A1 CA002239624A CA2239624A CA2239624A1 CA 2239624 A1 CA2239624 A1 CA 2239624A1 CA 002239624 A CA002239624 A CA 002239624A CA 2239624 A CA2239624 A CA 2239624A CA 2239624 A1 CA2239624 A1 CA 2239624A1
Authority
CA
Canada
Prior art keywords
schizophrenia
negative
treatment
cognitive symptoms
glycine uptake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002239624A
Other languages
French (fr)
Other versions
CA2239624C (en
Inventor
Daniel C. Javitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1996/019142 external-priority patent/WO1997020553A1/en
Publication of CA2239624A1 publication Critical patent/CA2239624A1/en
Application granted granted Critical
Publication of CA2239624C publication Critical patent/CA2239624C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A glycine uptake antagonist is administered for treating symptoms of psychosis and of schizophrenia.
CA002239624A 1995-12-07 1996-12-05 Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists Expired - Fee Related CA2239624C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US836195P 1995-12-07 1995-12-07
US60/008,361 1995-12-07
PCT/US1996/019142 WO1997020553A1 (en) 1995-12-07 1996-12-05 Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists

Publications (2)

Publication Number Publication Date
CA2239624A1 true CA2239624A1 (en) 1997-06-12
CA2239624C CA2239624C (en) 2007-08-14

Family

ID=38434486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002239624A Expired - Fee Related CA2239624C (en) 1995-12-07 1996-12-05 Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists

Country Status (1)

Country Link
CA (1) CA2239624C (en)

Also Published As

Publication number Publication date
CA2239624C (en) 2007-08-14

Similar Documents

Publication Publication Date Title
PT871440E (en) TREATMENT OF NEGATIVE AND COGNITIVE SYMPTOMS OF SCHIZOPHRENIA WITH ANTAGONISTS OF GLYCINE CAPTACAO
IL122242A0 (en) Combination of angiotensin II receptor and epoxy-steroidal aldosterone receptor antagonist
ZA964759B (en) Antithrombotic petidoyl heterocycles.
TW350844B (en) Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
CA2263561A1 (en) Thienopyrimidines
CA2264750A1 (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
MX9603259A (en) Treatment of normotensive glaucoma with angiotensin ii antagonists.
DE59700356D1 (en) Kombinationspräparat, enthaltend 5-methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid und n-(4-trifluormethylphenyl)-2-cyan-3-hydroxycrotonsäureamid
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
ZA962846B (en) Treatment of traveller's diarrhea
EP0584340A4 (en) Diagnosis and treatment of various neuralgias
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
HU9600455D0 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating hiv infections
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
CA2187444A1 (en) Antirestenosis protein
HUP9901353A3 (en) Use of an ace-inhibitor for producing pharmaceutical composition suitable for treating dyspeptic symptoms
MX9708557A (en) New pharmacological use of aii-receptor antagonists.
CA2239624A1 (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
ZA962847B (en) Treatment of traveller's diarrhea.
CH0509752H1 (en)
AU7083394A (en) Use of an angiotensin ii antagonist as an ocular hypotensive agent
AU9069291A (en) Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function
PL304335A1 (en) Drug for treating disorders in the form of compulsive ideas and movements
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents
CA2260863A1 (en) Treatment of psychotic disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151207

MKLA Lapsed

Effective date: 20151207